Biotech Values

[biocqr]

FGEN > FibroGen to present efficacy, safety analyses from Roxadustat Phase 3 Program

https://thefly.com/landingPageNews.php?id=3174772&headline=FGEN;AZN;ALPMY-FibroGen-to-present-efficacy-safety-analyses-from-Roxadustat-Phase--Program

FibroGen, Inc. (FGEN) and its partners, AstraZeneca (AZN) and Astellas Pharma Inc. (ALPMY), will present new analyses from the global Phase 3 program at the upcoming American Society of Nephrology Kidney Week 2020 Reimagined, assessing the potential of roxadustat, a first-in-class orally-administered hypoxia-inducible factor prolyl hydroxylase inhibitor, to revolutionize the treatment of anemia in patients with chronic kidney disease. The virtual congress will take place October 22-25, 2020. FibroGen and its partners will present 42 abstracts, including 2 late-breaker poster presentations, and 10 which have been accepted for oral presentation. Twenty-eight presentations on roxadustat for the treatment of anemia associated with CKD will further demonstrate the depth and breadth of the roxadustat global Phase 3 development program and build on the known clinical profile of roxadustat in treating a broad spectrum of CKD patients. Another 12 presentations on CKD anemia epidemiology and disease state outline the burden of anemia on CKD patients and their unmet medical need for innovative therapies. In addition, two late-breaking poster presentations will explore associations between cardiovascular safety and hemoglobin levels achieved with roxadustat in both non-dialysis-dependent and dialysis-dependent CKD patients. "Our roxadustat clinical data at ASN Kidney Week 2020 Reimagined demonstrate consistent efficacy and positive safety results across the continuum of chronic kidney disease patients with anemia, adding to the established body of evidence highlighting roxadustat as a potential foundational treatment for this condition affecting millions of patients," said Enrique Conterno, Chief Executive Officer, FibroGen. "We thank the investigators, study site staff, and patients who participated in the global roxadustat development program."

Read more at:
https://thefly.com/n.php?id=3174772